Oncology and Hematology - Global Oncology Academy

129-144 of 651

SERENA-6: Assessing Camizestrant’s Impact in HR+/HER2- Breast Cancer
SERENA-6: Assessing Camizestrant’s Impact in HR+/HER2- Breast Cancer
Project Oncology®
SERENA-6: Assessing Camizestrant’s Impact in HR+/HER2- Breast Cancer
Pavani Chalasani, MD, MPH; Erica L. Mayer, MD, MPH
- Pavani Chalasani, MD, MPH
- Erica L. Mayer, MD, MPH
Dato-DXd in Non-Small Cell Lung Cancer: Implications of TROPION-Lung01 Data
Dato-DXd in Non-Small Cell Lung Cancer: Implications of TROPION-Lung01 Data
Project Oncology®
Dato-DXd in Non-Small Cell Lung Cancer: Implications of TROPION-Lung01 Data
Jacob Sands, MD; Julia Rotow, MD
- Jacob Sands, MD
- Julia Rotow, MD
- Xiuning Le, MD, PhD
Dato-DXd’s Intracranial Efficacy in NSCLC: Insights from TROPION-Lung01
Dato-DXd’s Intracranial Efficacy in NSCLC: Insights from TROPION-Lung01
Project Oncology®
Dato-DXd’s Intracranial Efficacy in NSCLC: Insights from TROPION-Lung01
Jacob Sands, MD; Aaron Lisberg, MD
- Jacob Sands, MD
- Aaron Lisberg, MD
Advancing Endometrial Cancer Care: Molecular Targets and Emerging Therapies
Advancing Endometrial Cancer Care: Molecular Targets and Emerging Therapies
Project Oncology®
Advancing Endometrial Cancer Care: Molecular Targets and Emerging Therapies
Casey Cosgrove, MD
- Casey Cosgrove, MD
Growth Recovery After Tovorafenib in Pediatric Low-Grade Gliomas: New Data
Growth Recovery After Tovorafenib in Pediatric Low-Grade Gliomas: New Data
Project Oncology®
Growth Recovery After Tovorafenib in Pediatric Low-Grade Gliomas: New Data
Alexandria May, PharmD, BCPS; Daniel Landi, MD
- Alexandria May, PharmD, BCPS
- Daniel Landi, MD
Reducing Endometrial Cancer Risk: Targeting Modifiable Risk Factors
Reducing Endometrial Cancer Risk: Targeting Modifiable Risk Factors
Project Oncology®
Reducing Endometrial Cancer Risk: Targeting Modifiable Risk Factors
Brian Slomovitz, MD
- Brian Slomovitz, MD
Unmet Needs in Endometrial Cancer: Bridging Gaps in Treatment and Equity
Unmet Needs in Endometrial Cancer: Bridging Gaps in Treatment and Equity
Project Oncology®
Unmet Needs in Endometrial Cancer: Bridging Gaps in Treatment and Equity
Brian Slomovitz, MD
- Brian Slomovitz, MD
Beyond the Cure: Addressing Psychosocial Needs in Gene Therapy for SCD
Beyond the Cure: Addressing Psychosocial Needs in Gene Therapy for SCD
Project Oncology®
Beyond the Cure: Addressing Psychosocial Needs in Gene Therapy for SCD
Victoria Coleman-Cowger, PhD
- Victoria Coleman-Cowger, PhD
Targeting Ribosome Maturation: A Preclinical Strategy for Triple-Negative Breast Cancer
Targeting Ribosome Maturation: A Preclinical Strategy for Triple-Negative Breast Cancer
Project Oncology®
Targeting Ribosome Maturation: A Preclinical Strategy for Triple-Negative Breast Cancer
Ryan Quigley
- Ryan Quigley
Modern Era, New Outcomes: Survival Trends in Breast Cancer Brain Metastases
Modern Era, New Outcomes: Survival Trends in Breast Cancer Brain Metastases
Project Oncology®
Modern Era, New Outcomes: Survival Trends in Breast Cancer Brain Metastases
Ryan Quigley
- Ryan Quigley
Dexamethasone Timing and Infusion Reactions in HER2+ Breast Cancer
Dexamethasone Timing and Infusion Reactions in HER2+ Breast Cancer
Project Oncology®
Dexamethasone Timing and Infusion Reactions in HER2+ Breast Cancer
Early Adulthood Weight Gain Linked to Breast Tissue Complexity Changes
Early Adulthood Weight Gain Linked to Breast Tissue Complexity Changes
Project Oncology®
Early Adulthood Weight Gain Linked to Breast Tissue Complexity Changes
The Future of Immunotherapy: Advancing Care in Endometrial Cancer
The Future of Immunotherapy: Advancing Care in Endometrial Cancer
Project Oncology®
The Future of Immunotherapy: Advancing Care in Endometrial Cancer
Casey Cosgrove, MD
- Casey Cosgrove, MD
CLL17 Trial Insights: Fixed-Duration vs Continuous Therapy in Frontline CLL
CLL17 Trial Insights: Fixed-Duration vs Continuous Therapy in Frontline CLL
Project Oncology®
CLL17 Trial Insights: Fixed-Duration vs Continuous Therapy in Frontline CLL
Ryan Quigley
- Ryan Quigley
Doublet or Triplet? A Case-Based Debate in First-Line Choices for HR+/HER2- mBC 
Doublet or Triplet? A Case-Based Debate in First-Line Choices for HR+/HER2- mBC 
MinuteCE®
Doublet or Triplet? A Case-Based Debate in First-Line Choices for HR+/HER2- mBC 
Giuseppe Curigliano, MD, PhD; Komal Jhaveri, MD, FACP
1.00 program credit
- Giuseppe Curigliano, MD, PhD
- Komal Jhaveri, MD, FACP
1.00 program credit
Beyond Fulvestrant: Oral SERDs Redefining ER Targeting
Beyond Fulvestrant: Oral SERDs Redefining ER Targeting
MinuteCE®
Beyond Fulvestrant: Oral SERDs Redefining ER Targeting
Komal Jhaveri, MD, FACP
1.00 program credit
- Komal Jhaveri, MD, FACP
1.00 program credit

Previous
1
2
…
7
8
9
10
11
…
40
41
Next

9/11